OncoMatch/Clinical Trials/NCT06274047
PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.
Is NCT06274047 recruiting? Yes, currently enrolling (Sep 2026). This Phase 3 trial studies multiple treatments including Apalutamide and Androgen Deprivation Therapy for androgen axis suppression.
Treatment: Apalutamide · Androgen Deprivation Therapy — 1. Personalize treatment for prostate cancer based on how aggressive the disease is and 2. Learn if apalutamide-based treatment can help to reduce fatigue and other side effects of treatment in participants who are being treated with radiation therapy for prostate cancer, as compared to standard therapy.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Endocrine / hormonal
Other
Cancer type
Prostate Cancer
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Cannot have received: testosterone suppression after prostatectomy (gnrh agonist, gnrh antagonist, anti-androgen)
Exception: testosterone recovery after post-prostatectomy testosterone suppression (total testosterone > 190 ng/dl)
Cannot have received: testosterone suppression prior to prostatectomy
Exception: if the arteraai prostate test (post-rp) is required to risk stratify patients (those patients with psa ≤0.5 and no evidence of nodal involvement require arteraai prostate test (post-rp) to stratify)
Lab requirements
Blood counts
platelet count ≥ 100,000/µl; hemoglobin ≥ 9 g/dl
Kidney function
egfr ≥ 30 ml/min using mdrd formula
Liver function
bilirubin ≤1.5 x uln (gilbert's syndrome exception: if total bilirubin >1.5 x uln, direct bilirubin ≤1.5 x uln); ast ≤ 2.5 x uln; alt ≤ 2.5 x uln; serum albumin > 3.0 g/dl
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Rush MD Anderson · Chicago, Illinois
- University of Kansas Medical Center · Kansas City, Kansas
- Dana-Farber Cancer Institute · Boston, Massachusetts
- Memorial Sloan Kettering Cancer Center · New York, New York
- MD Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06274047 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior testosterone suppression after prostatectomy, testosterone suppression prior to prostatectomy disqualifies patients from enrollment.
Is this trial open to female patients?
No. This trial enrolls male patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages